SURGICAL ADHESIVE FOR JOINING AND HEALING MOIST TISSUE

用于连接和治愈湿组织的手术粘合剂

• 批准号: 6337703
• 负责人: MICHAEL S WILSON
• 金额: $ 10万
• 依托单位: EIC LABORATORIES, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-04-01 至 2001-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6337703
• 关键词: adhesions; aquatic organism; biological products; biomaterial development /preparation; biomaterial evaluation; biomaterial interface interaction; dihydroxyphenylalanine; fibrin; flavonoids; gelatin; high performance liquid chromatography; surgery material /equipment; wound healing

DESCRIPTION (Verbatim from the Applicant's Abstract): The development of a biologically based surgical adhesive for sealing or joining wet tissue is proposed. The material will overcome the problems of low-strength adhesion exhibited by currently available gelatin and fibrin surgical adhesives. The adhesive will be particularly effective at wet interfaces, at sites of active bleeding or in areas of high tension or pressure. The key innovation is the use of biologically safe proteins that have been modified to include highly-adhesive polyphenolic functional groups that displace surface fluid from wet tissue and form strong covalent bonds to the tissue during adhesive curing. These functional groups are responsible for adhesion in the high-strength water resistant protein glue produced by marine organisms such as mussels. In Phase I, adhesives will be prepared from polyphenol functionalized proteins through cross linking to form adhesive hydrogels and their efficacy as tissue adhesives evaluated in vitro as a function of compositional parameters. The adhesives will be compared with commercial gelatin and fibrin adhesives. In Phase II, surgical adhesive would be further developed through optimization of adhesive and elastomeric properties and evaluation of biodegradability, biocompatibility, longevity of adhesive bond and toxicity in several in vivo tissue types. PROPOSED COMMERCIAL APPLICATION: The commercial product is a surgical adhesive for internal use. The adhesive would be a two- part formulation for use in a variety of surgical procedures where sealing or joining of tissue is desired. EIC Laboratories would seek revenue through the licensing of adhesive technology.

描述（来自申请人的摘要的逐字）： 用于密封或接合湿组织的生物基外科粘合剂， 提出了该材料将克服低强度粘合的问题 由目前可用的明胶和纤维蛋白外科粘合剂显示。的 粘合剂将在湿界面、活性物质的位置处特别有效。 出血或在高张力或压力的区域。关键的创新在于 生物安全的蛋白质， 高粘性多酚官能团取代表面流体， 润湿纸巾并在粘合剂固化期间与纸巾形成强共价键。 这些官能团负责在高强度水中的粘附 由贻贝等海洋生物产生的耐腐蚀的蛋白质胶。同相 一、将多酚功能化蛋白质通过 交联形成粘合性水凝胶及其作为组织粘合剂的功效 在体外作为组成参数的函数进行评价。粘合剂 将与商业明胶和纤维蛋白粘合剂进行比较。在第二阶段， 通过优化粘合剂，将进一步开发外科粘合剂 和弹性体性能以及生物降解性的评价， 生物相容性、粘合剂粘合的寿命和几种体内毒性 组织类型。 拟定商业应用： 市售产品是一种内部使用的外科粘合剂。 粘合剂是两个- 用于各种外科手术的部件制剂 是需要的。 EIC实验室将通过胶粘剂技术的许可证来寻求收入。